A recent editorial published in the ESMO Daily Reporter raises questions about the impact of precision medicine in personalized cancer care, considering that "patients are still largely treated according to the primary organ where their cancer originates." Tumour-agnostic agents, drugs approved if cancer cells cause gene or protein changes, no matter where in the body the cancer originated, calls for physicians and patients to engage in precision medicine, "a first step toward a common understanding...in which tissue-agnostic development should be preferred to conventional trials."
Click here to learn more.
No comments:
Post a Comment